Therefore, genomic changes in tumors from 68 patients with advanced melanomas, who progressed on anti-CTLA-4 treatment or were anti-CTLA-4 therapy-naïve, before and after anti-PD-1 initiation were determined [81]. This evidence concerns the gene PDCD1 and melanoma.